+2,907.7%
AMD vs MRNA
+951.6%
+1,956.1%
-65.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +5.9% | -7.0% | +12.8% | +6.5% |
| 7D | +44.7% | -4.2% | +48.9% | +45.3% |
| 30D | -3.3% | +7.0% | -10.3% | -3.9% |
| 3M | +21.2% | +263.4% | -242.2% | -1.4% |
| 6M | +30.6% | +334.3% | -303.7% | +1.9% |
| YTD | +173.3% | +684.5% | -511.2% | +92.1% |
| 1Y | +126.1% | +766.2% | -640.1% | +56.0% |
| 3Y | +393.5% | +230.3% | +163.3% | +275.9% |
| 5Y | +295.8% | +0.1% | +295.7% | +244.1% |
| All | +2,907.7% | +951.6% | +1,956.1% | +1,625.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling